A “practice-changing” immunotherapy drug combination demonstrated inhibition of two main immune checkpoints in a trial assessing efficacy in metastatic melanoma.
List view / Grid view
US National Cancer Institute (NCI)
Researchers reveal dose-adjusted (DA) EPOCH-R chemotherapy regimen was effective across all ages of Burkitt lymphoma patients in a Phase II clinical trial.
The FDA and EMA have granted Orphan Drug Designation to zotiraciclib, currently the subject of two separate Phase Ib clinical trials in glioblastoma.